Skip to Content

Other Cancer Trials

AFT-28: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin in VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
Aims: The purpose of this study is to gather information oral anticoagulants versus the usual care of low-molecular weight heparin/warfain in the treatment of blood clots.
Diagnosis: Any cancer except leukemia
Principal Investigator: Afonso Tafur, MD
IRB Approval Number: EH17-042
Sponsor: Alliance Foundation Trials
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

ACCRU SC1601: A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondard Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Aims: The purpose of this study is to gather information regarding the extension of time of treatment on oral anticoagulants.
Diagnosis: Any cancer except leukemia
Principal Investigator: Afonso Tafur, MD
IRB Approval Number: EH17-300
Sponsor: Academic and Community Cancer Research United
Contact: For further information, please contact Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

A221602: Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) A Phase III Randomized, Double-Bline, Placebo-Controlled Trial
Aims: The purpose of this study is to see if olanzapine without fosaprepitant is as effective as olanzapine with fosaprepitant.
Diagnosis: Any cancer receiving HEC
Principal Investigator: Lauren Wiebe, MD
IRB Approval Number: EH19-182
Sponsor: Alliance
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

 

EAY131: Molecular Analysis for Therapy Choice (MATCH)
Aims: This study will look at assigning treatment for patients whose cancer has become worse after standard treatment. Patients will have a genomic analysis of their tumor which will direct appropriate targeted therapy.
Diagnosis: any solid tumor
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH15-387
Sponsor: ECOG-ACRIN/NCI 
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes (limited)